top of page
The Professional Network for Healthcare Experts
Sobi licenses lacutamab from Innate Pharma in T-cell lymphoma deal worth up to $580 million
The partnership gives Sobi potential global commercial and development rights to the first-in-class anti-KIR3DL2 antibody while funding Innate’s Phase III programme in cutaneous T-cell lymphoma.
nuaxia
Aug 103 min read
Sobi moves to acquire full control of Pint Pharma to expand Latin American rare disease platform
The transaction would give Sobi full ownership of a specialist commercialisation platform spanning seven Latin American markets, building on its $105 million investment in Pint Pharma in 2025.
nuaxia
Aug 103 min read
bottom of page